Navigation Links
Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
Date:9/25/2008

4.40 kg and 2.45+/-4.37 kg occurred with liraglutide 1.2 mg and 1.8 mg, respectively, versus a weight gain of 1.12+/-4.24 kg with glimepiride.

There were no major hypoglycemic episodes reported during the study. The rate of minor hypoglycemia was statistically significantly lower in both liraglutide dose groups compared with the glimepiride-treated group. The most common gastrointestinal-related adverse events with liraglutide were nausea, diarrhea and vomiting, and most were transient. Other adverse events reported included flu-like symptoms.

About Liraglutide

Liraglutide is a once-daily human analog of the naturally occurring hormone Glucagon-Like Peptide-1 (GLP-1). Liraglutide works by stimulating the release of insulin only when blood sugar levels become too high and by inhibiting appetite. On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the United States as well as a marketing authorization application to the European Medicines Agency in Europe for the approval of liraglutide for the treatment of patients with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 14, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) 3a program involved about 4000 patients with type 2 diabetes in 40 countries.

The data published early online and in an upcoming edition of The Lancet is from the LEAD(TM) 3 study, one of five randomized, controlled, double-blinded studies that make up the phase 3a program for liraglutide.

Data from the LEAD(TM) 3 study have previously been reported on by Novo Nordisk in a Stock Exchange Announcement on December 11, 2007, and in a press release on June 9, 2008, in connection with the American Diabetes Association meeting in San Francisco.

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabe
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
4. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
5. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
6. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
7. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
8. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
10. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
11. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... LONDON , June 30, 2015 ... Street issued a survey to Rosacea sufferers as part of ... what treatments Rosacea sufferers found effective for their Rosacea. The ... age, and comprised 47% men and 53% women. ... of survey participants did not consider or attempt to visit ...
(Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015  Avanir Pharmaceuticals, Inc. today ... showing that treatment with NUEDEXTA ® was ... of pseudobulbar affect (PBA) in patients with traumatic ... distressing condition characterized by sudden and uncontrollable outbursts ... diseases or brain injury. PRISM II is a ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... Top-line Data Expected in August -, EXTON, ... today the completion of the pivotal efficacy portion ... Isolagen,Therapy(TM) for the treatment of nasolabial folds, or ... the primary efficacy follow-up visit,and collation of this ...
... ... Professionals, VOORHEES, N.J., July 1 ... a wide spectrum of,severity, ranging from mild diarrhea to pseudomembranous colitis ... who develop an initial,case of CDI.(1) These patients are at increased ...
Cached Medicine Technology:Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles 2Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles 3Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2
(Date:6/30/2015)... ... June 30, 2015 , ... CCAR is pleased to announce its ... in Hartford, Willimantic and Bridgeport. This month, staff member Jim Higgins left his ... He is excited to take on this role of organizing peer recovery support ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, ... ... Physicians News Digest discussed the advantages that fat transfer procedures had ... breast reconstruction using fat transfer techniques create breasts that “look and feel natural,” ...
(Date:6/30/2015)... GA (PRWEB) , ... June 30, 2015 , ... After ... by the U.S. Food and Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for ... with an SPF rating of 35, hits the market just in time to help ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... response profiling test to help oncologists provide personalized cancer treatment, will be ... assay provides the oncologist with valuable insight on how a specific patient’s ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... medical device market research, has launched a new reimbursement insurance policy tracking and ... professionals to receive US insurance policy and rate updates in real-time from hundreds ...
Breaking Medicine News(10 mins):Health News:The Connecticut Community for Addiction Recovery takes Recovery Coaching to a new level 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2
... Fla., Jan. 7 - 3M, in,partnership with Roush Fenway Racing, ... paint scheme to the American Red Cross for two races,during ... space on the,rear side panel of the car where the ... year., (Photo: http://www.newscom.com/cgi-bin/prnh/20080107/DC10974 ), "This is ...
... WellPoint, Inc. (NYSE: WLP ) today,announced that ... Technology,and Government Services Business Unit, has been recognized ... Computerworld,s 2008 Premier 100 honors the 100 ... and motivating employees; envisioning,innovative solutions to business challenges; ...
... 7 Barc, the leader in the $1.8 billion,African-American ... of its new travel size for its market leading ... product is now available,in a convenient 1.7 oz bottle ... reduces irritation and ingrown hairs due to shaving,preventing new ...
... cells and cancer stem cells reveals that the cancer ... of development. The research, published by Cell Press in ... understanding of glioma pathophysiology and provides new directions for ... types of tumors. , Tumor-initiating cells with stem like ...
... COLUMBUS , Ohio New research suggests that at any ... (EMTs) and paramedics in the United States miss work because ... , A study examining how common these injuries are and ... professionals also suggests that in one year, an estimated 8.1 ...
... less food had same effect on weight at age 2, study ... toddlers consume, either by trying to get them to eat less ... weight by the age of 2, new British research suggests. , ... always in the best interest of a young child, according to ...
Cached Medicine News:Health News:3M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 2Health News:3M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 3Health News:WellPoint Executive Mark Boxer Recognized as One of Computerworld's 2008 Premier 100 IT Leaders 2Health News:WellPoint Executive Mark Boxer Recognized as One of Computerworld's 2008 Premier 100 IT Leaders 3Health News:Forever young: Differentiation blocked in tumor stem cells 2Health News:Emergency responders at high risk to miss work because of injuries 2Health News:Emergency responders at high risk to miss work because of injuries 3Health News:Parental Control of Eating Leads to Lighter Toddlers 2Health News:Parental Control of Eating Leads to Lighter Toddlers 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: